Cargando…
Expression of CDK7 correlates with molecular subtypes and predicts clinical outcomes in breast cancer
BACKGROUND: Cyclin-dependent kinase 7 (CDK7) belongs to CDK family, which is involved in transcriptional activity and cell cycle progression. Recent studies have suggested that CDK7 inhibitor is effective in the treatment of breast cancer, whereas, the efficacy of antitumor response varies significa...
Autores principales: | Tang, Lin, Zhu, Chengjun, Jin, Juan, Wang, Xin, Yu, Lingyue, Guan, Xiaoxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799258/ https://www.ncbi.nlm.nih.gov/pubmed/35116400 http://dx.doi.org/10.21037/tcr-20-2911 |
Ejemplares similares
-
SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer
por: Tang, Lin, et al.
Publicado: (2020) -
Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes
por: Fang, Cheng, et al.
Publicado: (2017) -
CDK7 Inhibition Is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition
por: McDermott, Martina S. J., et al.
Publicado: (2020) -
MYC dysfunction modulates stemness and tumorigenesis in breast cancer
por: Liu, Yiqiu, et al.
Publicado: (2021) -
Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes
por: Wang, Haoyu, et al.
Publicado: (2020)